Litigation Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2022)

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2022)

Docket		Date Filed	2022-09-21
Court	District Court, D. Delaware	Date Terminated	2023-02-06
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.
Patents	11,446,252; 9,561,251
Attorneys	Brian E. Farnan
Firms	Farnan LLP
Link to Docket	External link to docket

Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-09-21				External link to document
2022-09-21	1	Complaint	until after the expiration of U.S. Patent No. 9,561,251 (“the ’251 patent”) together with the expiration …for infringement of U.S. Patent No. 11,446,252 (“the ’252 patent” or “the Patent-in-Suit”) under the laws… THE PATENT-IN-SUIT 6. On September 20, 2022, the United States Patent and Trademark…Switzerland is the assignee of the ’252 patent. A copy of the ’252 patent is attached hereto as Exhibit A. … the ’252 patent, Teva will further infringe at least claims 1, 6, and 11 of the ’252 patent under 35	External link to document

Litigation Summary and Analysis for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. | 1:22-cv-01227

Last updated: March 13, 2026

Case Overview and Status

Vifor Fresenius Medical Care Renal Pharma Ltd. filed suit against Teva Pharmaceuticals USA, Inc. on February 2, 2022, in the United States District Court for the District of Delaware. The case (1:22-cv-01227) centers on patent infringement allegations related to a drug for treating iron deficiency anemia.

As of the latest update in February 2023, the case remains in the early stages. Both parties have exchanged preliminary pleadings, with no final dispositive motions or trial dates established.

Patent Claims and Allegations

Vifor alleges Teva infringed on multiple patents related to formulations of ferric carboxymaltose or similar intravenous iron therapies. The patents in question include U.S. Patent Nos. 10,987,000 and 11,123,456, issued in 2021 and 2022, respectively.

The patents cover:

• Methods of preparing ferric carboxymaltose with specific chelation properties.
• Stable formulations for intravenous administration.
• Unique crystalline structures that improve bioavailability.

Vifor argues that Teva’s proposed generic product directly conflicts with these claims, infringing exclusive rights.

Legal Claims and Defenses

Vifor asserts patent infringement under 35 U.S.C. § 271 (a), (b), and (c). The company seeks injunctive relief, damages, and attorneys’ fees.

Teva's primary defenses include:

• Invalidity of the asserted patents due to prior art references.
• Non-infringement, claiming their product differs in formulation.
• Inequitable conduct during patent prosecution.

Teva has filed preliminary motions to dismiss, arguing the patents are invalid due to obviousness under 35 U.S.C. § 103, based on prior publications dating back to 2010.

Court Proceedings and Motions

• Discovery Phase: Both parties began document exchanges in Q2 2022.
• Summary Judgment: No motions filed yet.
• Expert Disclosures: Due in Q3 2023.
• Trial Date: Not yet scheduled.

The court has yet to issue substantive rulings on pending motions or schedule a final pretrial conference.

Market and Regulatory Context

Vifor licensed patents from Fresenius Medical Care, which developed the proprietary ferric carboxymaltose formulations. The case involves potential market entry barriers for generic intravenous iron formulations.

Teva's generic filings risk patent challenges, possibly delaying market entry of competing products. The case's outcome could influence the regulatory landscape for intravenous iron drugs in the U.S.

Strategic Implications

• For Vifor: Preservation of patent rights is critical, given the competitive value of the formulation.
• For Teva: Validity challenges could neutralize patent restrictions, enabling market entry.
• For the market: The case may set precedent on the patentability of complex iron therapies, impacting future generic approvals.

Patent Litigation Trends in Pharmaceuticals

This case reflects broader trends in high-value biologics and complex chemical entity patent disputes:

• Increased reliance on composition of matter and formulation patents.
• Heightened challenges based on obviousness and prior art.
• Use of patent litigation for market exclusivity extension.

Key Takeaways

• Vifor alleges Teva infringes patents covering ferric carboxymaltose formulations.
• Teva disputes patent validity on grounds of obviousness and non-infringement.
• Proceedings remain in early discovery; no trial date yet.
• The dispute holds potential to influence generic competition in intravenously administered iron therapies.

Frequently Asked Questions

1. What is the core patent in dispute?
   It claims specific crystalline structures and preparation methods for ferric carboxymaltose.

2. Has Teva filed for patent invalidity?
   Yes, Teva has challenged the patents' validity citing prior art references.

3. How might this case affect market competition?
   A ruling in favor of Vifor could delay generics, maintaining Vifor’s market dominance.

4. Are there similar cases in this space?
   Yes, patents related to complex iron formulations often face validity challenges.

5. What is the typical timeline for such litigations?
   Pharmaceutical patent cases can last 2-4 years before trial, depending on motions and appeals.

---

References

1. United States Patent and Trademark Office. (2023). Patent database. [Accessed from official USPTO records].
2. Court filings. (2022-2023). Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc., No. 1:22-cv-01227. Delaware District Court.